Format

Send to

Choose Destination
J Craniomaxillofac Surg. 2016 Mar;44(3):265-70. doi: 10.1016/j.jcms.2015.12.005. Epub 2015 Dec 20.

Osteonecrosis of the jaw in patients treated with denosumab for metastatic tumors to the bone: A series of thirteen patients.

Author information

1
Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
2
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA.
3
Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. Electronic address: estiloc@mskcc.org.

Abstract

This case series describes the course of osteonecrosis of the jaw (ONJ) in thirteen patients with metastatic bone tumors treated solely with denosumab. Patients on denosumab may be more prone to developing ONJ even without a risk/precipitating factor and they may develop ONJ early in their denosumab therapy. The outcomes of ONJ in ten patients following a period of denosumab discontinuation after the onset of ONJ were: 3 had complete resolution of symptoms, 4 patients' ONJ progressed, 2 patients' ONJ was unchanged and in 1 patient there was partial ONJ resolution. The role of drug discontinuation prior to an invasive dental procedure or after the onset of ONJ still remains debatable.

KEYWORDS:

Denosumab; Metastatic bone disease; Osteonecrosis of the jaw

PMID:
26782845
PMCID:
PMC4784099
DOI:
10.1016/j.jcms.2015.12.005
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center